Can you explain Henoch‑Schönlein purpura (IgA vasculitis) in great detail and precisely?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Henoch-Schönlein Purpura (IgA Vasculitis): Comprehensive Overview

Definition and Nomenclature

IgA vasculitis (IgAV), formerly known as Henoch-Schönlein purpura, is an immune complex-mediated small-vessel vasculitis characterized by IgA1-dominant immune deposits affecting small vessels throughout the body 1. The disease was renamed from Henoch-Schönlein purpura to IgAV in the 2012 Chapel Hill Consensus Conference nomenclature, reflecting the understanding that abnormal IgA deposition within vessel walls represents the defining pathophysiological feature 1.

The historical context is important: Johann Lukas Schönlein first described the clinical association of purpura and arthritis in 1837, and Eduard Henoch later added gastrointestinal and renal manifestations in 1874 2.

Pathophysiology

The disease mechanism centers on circulating abnormally glycosylated IgA1 and IgA1-anti-IgA1 IgG immune complexes that deposit in small vessel walls 1. These immune complexes activate complement (particularly C3) and trigger neutrophil infiltration, leading to vascular inflammation and tissue damage 1, 3.

Key pathophysiological features include:

  • Galactose-deficient IgA1 complexes that deposit in vessel walls
  • Neutrophil activation via IgA Fc receptor (FcαRI/CD89), causing migration and tissue damage
  • Complement activation with C3 deposition alongside IgA
  • Endocapillary hypercellularity with prominent neutrophilic infiltration 1

Clinical Manifestations

Cutaneous Involvement

Palpable purpura is the hallmark and mandatory criterion for classification, typically predominating on the lower extremities 1. The skin lesions may also present as maculopapular or papular rash, and can extend above the waistline in more severe cases 1.

Gastrointestinal Involvement

Abdominal pain is very common, occurring in 37-65% of adult cases 1, 4. Severe gastrointestinal involvement includes:

  • Massive gastrointestinal bleeding
  • Intussusception
  • Intestinal infarction
  • Intestinal perforation

These severe manifestations are potentially life-threatening and require urgent management 1.

Renal Involvement (IgAV-Nephritis)

Kidney involvement should be suspected with haematuria, proteinuria, or reduced eGFR 1. Severe presentations include:

  • Nephrotic syndrome (proteinuria with edema and hypoalbuminemia)
  • Rapidly progressive glomerulonephritis (RPGN) with >50% eGFR decline over ≤3 months

Critical prognostic factors for progression to kidney failure:

  • eGFR <60 ml/min/1.73 m² at presentation
  • Proteinuria >0.5 g/day (or >0.5 g/g creatinine ratio)
  • Male sex, Black ethnicity, diabetes 1

Histologically, IgAV-nephritis shows more prominent endocapillary hypercellularity (particularly neutrophilic), more frequent extracapillary proliferation (crescents), and more extensive capillary-wall IgA deposition compared to isolated IgA nephropathy 1.

Joint Involvement

Arthralgia and arthritis commonly affect large joints, particularly knees and ankles.

Diagnostic Approach

Clinical Diagnosis

The diagnosis relies on the combination of clinical, laboratory, and histological findings 1. Evidence of predominant IgA tissue deposits with compatible histology (leukocytoclastic vasculitis or mesangioproliferative glomerulonephritis) in a patient with suggestive clinical presentation strongly supports the diagnosis 1.

Important caveat: The absence of IgA deposits does not exclude the diagnosis, as direct immunofluorescence can be variable in adults 5.

Classification Criteria

The EULAR/PRINTO/PReS Ankara 2008 criteria can be applied to classify adult-onset IgAV 1. These require:

  • Mandatory: Palpable purpura (typically lower limb predominant)
  • Plus one or more of:
    • Abdominal pain
    • Kidney involvement (haematuria/proteinuria)
    • Arthritis or arthralgia
    • Histopathological evidence of IgA deposition

Critical distinction: These are classification criteria for research studies, not diagnostic criteria for clinical practice 1.

Trigger Identification

At diagnosis, search for potential triggers 1:

  • Acute infections (particularly upper respiratory tract infections)
  • Recently introduced drugs or vaccines
  • Chronic infections (chronic viral hepatitis, oral/dental disease)
  • Underlying malignancies (solid or hematological)
  • Chronic liver disease
  • IgA monoclonal gammopathies

The disease shows seasonal variation with twice the incidence during fall and winter, suggesting environmental triggers 3.

Kidney Biopsy Indications

A kidney biopsy is indicated when 1:

  • Diagnostic uncertainty regarding IgAV-nephritis in systemic vasculitis
  • Rapid worsening of kidney function (>30% eGFR decline in 1-2 weeks)
  • Persistent proteinuria >0.5 g/g for 2-4 weeks despite treatment

Histology should be classified using the MEST-C score (Mesangial hypercellularity, Endocapillary hypercellularity, Segmental glomerulosclerosis, Tubular atrophy/interstitial fibrosis, Crescents) 1.

Adult vs. Pediatric Disease

Adult-onset IgAV is fundamentally more severe than pediatric disease 6, 7, 5:

  • Higher rates of renal involvement (up to 80% in adults vs. 20-50% in children)
  • Greater risk of progression to end-stage renal disease (10.8-21.3% in adults) 1
  • More severe gastrointestinal complications
  • Higher long-term morbidity and mortality
  • More extensive glomerulosclerosis and interstitial fibrosis 1

Treatment Algorithm

Mild Disease (Skin/Joint Involvement Only)

Symptomatic treatment is sufficient 1:

  • Analgesia for pain
  • Rest and supportive care
  • Alternative options: Colchicine or dapsone for persistent skin lesions 1

Moderate Disease

For persistent proteinuria or mild kidney dysfunction:

  • Renin-angiotensin-aldosterone system (RAAS) blockade with ACE inhibitor or ARB 1, 8
  • SGLT2 inhibitors for patients at risk of progressive kidney function loss 8
  • Monitor blood pressure, eGFR, and proteinuria at 3 and 6 months 1
  • Consider kidney biopsy if disease progresses 1

Severe Disease

For rapidly progressive glomerulonephritis, nephrotic syndrome, or severe gastrointestinal involvement 1:

Primary therapy:

  • Prednisone 1 mg/kg/day (maximum 60 mg/day) 1
  • Taper over 6 months
  • ± Intravenous methylprednisolone pulses for severe presentations
  • ± Cyclophosphamide for rapidly progressive disease 1, 8
  • ± Plasmapheresis in select cases 1

Rapidly progressive IgAV-nephritis specifically:

  • Treat according to KDIGO 2024 ANCA-Associated Vasculitis guidelines
  • Cyclophosphamide plus systemic glucocorticoids 8
  • Note: Insufficient evidence for rituximab in rapidly progressive IgAV 8

Refractory or Relapsing Disease

Consider alternative immunosuppression 1:

  • B-cell depletion therapy (rituximab)
  • Mycophenolate mofetil (MMF)

Chronic Kidney Disease Management

For established CKD from IgAV-nephritis 1:

  • RAAS inhibitors and/or SGLT2 inhibitors
  • Sodium-restricted diet
  • Blood pressure control (target <130/80 mmHg)
  • Cardiovascular risk factor management

Emerging therapies for IgA-mediated disease:

  • Sparsentan (dual endothelin-1 and angiotensin II receptor blocker) - replaces rather than adds to RASi 8
  • Complement inhibitors (under investigation)
  • Mucosal immune system targeting (under investigation) 7

Monitoring and Prognosis

Surveillance Strategy

Continuous monitoring of renal parameters is essential, even after apparent remission 9, 5:

  • Urinalysis and proteinuria quantification
  • Serum creatinine and eGFR
  • Blood pressure monitoring
  • Duration: Several months to years, as nephritis can appear subclinically weeks after initial presentation 9

Prognostic Factors

Poor renal outcomes associated with 1:

  • Proteinuria >1 g/day
  • eGFR <60 ml/min/1.73 m² at presentation
  • eGFR <30 ml/min/1.73 m² (very high risk)
  • Glomerular sclerosis >10%
  • Moderate-to-severe interstitial fibrosis and tubular atrophy
  • Glomerular necrosis >10%

Mortality risk factors 1:

  • Advanced age
  • Purpura above the waistline
  • Pre-existing heart failure

Kidney failure outcomes:

  • 10.8-21.3% of adults with IgAV-nephritis develop kidney failure 1
  • 92.6% of those who develop kidney failure do so within 10 years 1
  • 48.1% develop kidney failure within 3 years of diagnosis 1

Critical Clinical Pitfalls

Common diagnostic errors:

  • Misattribution to drug reactions when purpura follows antibiotic use 10
  • Confusion with diverticulitis when abdominal pain predominates 10
  • Failure to recognize adult disease due to focus on pediatric criteria 5
  • Missing delayed renal involvement by discontinuing monitoring too early 9

Management errors:

  • Underestimating severity in adults compared to children
  • Delaying immunosuppression in rapidly progressive disease
  • Failing to screen for underlying malignancy or chronic infection in adults
  • Not obtaining kidney biopsy when indicated for prognostic information

Special Populations

Pregnancy

Women of childbearing potential require preconception counseling 8:

  • Discontinue RASi, SGLT2i, and sparsentan before conception
  • Optimize blood pressure with pregnancy-compatible medications
  • Systemic glucocorticoids may be used during pregnancy
  • Consider trial of immunosuppression before conception in high-risk patients

The disease course in adults is fundamentally different from children, requiring heightened vigilance for severe complications, particularly renal and gastrointestinal involvement, with treatment intensity matched to disease severity and close long-term monitoring for delayed renal manifestations.

Related Questions

What are the causes and predisposing factors of Henoch‑Schönlein purpura (IgA vasculitis)?
Can a 1-year-old child develop IgA-mediated small-vessel vasculitis (Henoch‑Schönlein purpura)?
What is the prognosis of Henoch‑Schönlein purpura (IgA vasculitis) and what are the recommended monitoring and treatment strategies for renal involvement?
What is the appropriate management and treatment strategy for IgA vasculitis (formerly Henoch‑Schönlein purpura)?
Can you briefly differentiate the three IgA glomerulonephritides (primary IgA nephropathy, IgA vasculitis/Henoch‑Schönlein purpura, and IgA‑dominant infection‑associated glomerulonephritis)?
What are the therapeutic options for non‑hypertrophic lichen planus on the back, which class of topical corticosteroid should be used, and how should the taper be performed and over what duration?
What are the South African guidelines for managing Pneumocystis jirovecii pneumonia in an HIV‑positive patient?
In a patient with Hashimoto thyroiditis who has a suppressed TSH of 0.05 mU/L while taking levothyroxine 100 µg daily, how should the daily levothyroxine dose be adjusted?
Is tranexamic acid contraindicated in patients with congenital heart disease complicated by pulmonary arterial hypertension?
What is the appropriate management of epistaxis in a patient with congenital heart disease and pulmonary arterial hypertension?
What do expert societies recommend regarding the application frequency of Dermoval (clobetasol propionate) in the acute phase of cutaneous non‑hypertrophic lichen plan—once daily or twice daily?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.